



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/00	A2	(11) International Publication Number: WO 00/53165 (43) International Publication Date: 14 September 2000 (14.09.00)															
(21) International Application Number: PCT/EP00/02062 (22) International Filing Date: 9 March 2000 (09.03.00) (30) Priority Data: <table border="0"> <tr> <td>9905315.9</td> <td>9 March 1999 (09.03.99)</td> <td>GB</td> </tr> <tr> <td>9905300.1</td> <td>9 March 1999 (09.03.99)</td> <td>GB</td> </tr> <tr> <td>9905310.0</td> <td>9 March 1999 (09.03.99)</td> <td>GB</td> </tr> <tr> <td>9905307.6</td> <td>9 March 1999 (09.03.99)</td> <td>GB</td> </tr> <tr> <td>9905314.2</td> <td>9 March 1999 (09.03.99)</td> <td>GB</td> </tr> </table> (71) Applicant (for all designated States except US): MAX-DELBÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN [DE/DE]; Robert-Rössle-Strasse 10, D-13125 Berlin (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): ANKER, Stefan [DE/DE]; Hedrichplatz 25, D-10367 Berlin (DE). COATS, Andrew [AU/GB]; 105 A Cadogan Gardens, London SW3 2RF (GB). VOLK, Hans-Dieter [DE/DE]; Rathausstrasse 11, D-10178 Berlin (DE). SCHUMANN, Ralf, Reiner [DE/DE]; Buchenallee 104, D-16341 Zepernick (DE). PLAUTH, Mathias [DE/DE]; Paderbornerstrasse 9, D-10709 Berlin (DE). LOCHS, Herbert [DE/DE]; Helmstedter Strasse 8, D-10717 Berlin (DE).		9905315.9	9 March 1999 (09.03.99)	GB	9905300.1	9 March 1999 (09.03.99)	GB	9905310.0	9 March 1999 (09.03.99)	GB	9905307.6	9 March 1999 (09.03.99)	GB	9905314.2	9 March 1999 (09.03.99)	GB	(74) Agent: BAUMBACH, Fritz; Robert-Rössle-Strasse 10, D-13125 Berlin (DE). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
9905315.9	9 March 1999 (09.03.99)	GB															
9905300.1	9 March 1999 (09.03.99)	GB															
9905310.0	9 March 1999 (09.03.99)	GB															
9905307.6	9 March 1999 (09.03.99)	GB															
9905314.2	9 March 1999 (09.03.99)	GB															
(54) Title: THERAPY AND USE OF COMPOUNDS IN THERAPY (57) Abstract <p>The present invention relates to therapy and the use of agents in the therapy of cachexia and wasting syndromes due to diseases other than congestive heart failure. Cachexia occurs in a number of other chronic diseases, like liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis. Cachexia and weight loss are linked to inflammatory processes and they are linked to increased mortality and/or morbidity. Cytokine activation is a potential causal mechanism for the development of cachexia also in these other diseases. The invention describes a method of treating or ameliorating body wasting or cachexia in a patient with liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis in a patient. The method comprises administering to the patient an effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin (lipopolysaccharide; LPS). The invention describes also a method of treating, preventing or ameliorating endotoxin-mediated immune activation in body wasting or cachexia in a patient with liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis. The method comprises administering to the patient an effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin (lipopolysaccharide; LPS).</p>																	